California-based AI drug discovery startup Genesis Therapeutics has raised USD 200 million in a Series B funding round co-led by a US-based life sciences-focused investor (name undisclosed) and Andreessen Horowitz Bio + Health, with participation from other existing and new investors. This brings the total funds raised by the company to over USD 280 million.
The funds will be used to further develop the company’s AI-powered Genesis Exploration of Molecular Spaces (GEMS) platform, advance its pipeline of therapeutic candidates into clinical development, and further expand its pipeline with new programs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.